Fulgent Genetics, Inc.
$16.18
▲
2.31%
2026-04-21 06:52:01
www.fulgentgenetics.com
NGM: FLGT
Explore Fulgent Genetics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$481.31 M
Current Price
$16.18
52W High / Low
$31.04 / $13.46
Stock P/E
—
Book Value
$35.78
Dividend Yield
—
ROCE
-8.07%
ROE
-5.51%
Face Value
—
EPS
$-1.97
Exp Qtr EPS
—
Sector
Healthcare
Industry
Diagnostics & Research
Employees
1,315
Beta
0.89
Debt / Equity
0.73
Current Ratio
6.48
Quick Ratio
6.35
Forward P/E
-9.72
Price / Sales
1.4
Enterprise Value
$117.34 M
EV / EBITDA
-1.8
EV / Revenue
0.36
Rating
None
Target Price
$24.33
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ENDRA Life Sciences Inc. | $6.01 | — | $7.46 M | — | -281.17% | -2.92% | $11.96 / $2.9 | $0.22 |
| 2. | IQVIA Holdings Inc. | $175.62 | 22.46 | $29.52 B | — | 10.59% | 21.44% | $247.05 / $134.65 | $38.34 |
| 3. | IDEXX Laboratories, Inc. | $580.27 | 44.49 | $46.26 B | — | 61.76% | 66.2% | $769.98 / $402.85 | $20.14 |
| 4. | Veracyte, Inc. | $33.45 | 39.66 | $2.63 B | — | 5.82% | 5.34% | $50.71 / $22.61 | $16.5 |
| 5. | Quest Diagnostics Incorporated | $200.41 | 22.15 | $22.16 B | 1.76% | 11.16% | 14.75% | $213.5 / $160.02 | $65.18 |
| 6. | GRAIL, Inc. | $51.2 | — | $2.1 B | — | -18.79% | -16.07% | $118.84 / $25.56 | $63.92 |
| 7. | iSpecimen Inc. | $0.13 | — | $4.05 M | — | -355.55% | -3.28% | $3.18 / $0.1 | $0.31 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 83.34 M | 84.07 M | 81.8 M | 73.46 M | 76.21 M | — |
| Operating Profit | -36.24 M | -15.35 M | -19.71 M | -19.8 M | -16.14 M | — |
| Net Profit | -23.42 M | -6.61 M | -18.96 M | -11.53 M | -5.89 M | — |
| EPS in Rs | -0.81 | -0.23 | -0.66 | -0.4 | -0.2 | -0.48 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 322.67 M | 283.47 M | 289.21 M | 618.97 M |
| Operating Profit | -91.1 M | -73.92 M | -75.3 M | 181.5 M |
| Net Profit | -60.51 M | -42.71 M | -167.82 M | 143.4 M |
| EPS in Rs | -2.1 | -1.48 | -5.82 | 4.97 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.21 B | 1.22 B | 1.24 B | 1.39 B |
| Total Liabilities | 106.81 M | 90.81 M | 102.04 M | 116.18 M |
| Equity | 1.11 B | 1.13 B | 1.14 B | 1.27 B |
| Current Assets | 550.49 M | 353.57 M | 507.85 M | 627.87 M |
| Current Liabilities | 84.97 M | 72.9 M | 73.02 M | 88.11 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -101.64 M | 21.06 M | 27 M | 253.52 M |
| Investing CF | 111.37 M | -58.35 M | 38.9 M | -261.31 M |
| Financing CF | -14.79 M | -4.85 M | -47.78 M | -77.14 M |
| Free CF | -124.21 M | -19.25 M | 4.8 M | 234.75 M |
| Capex | -22.57 M | -40.31 M | -22.21 M | -18.77 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -1.99% | -53.27% | — | — |
| Earnings Growth % | 74.55% | -217.03% | — | — |
| Profit Margin % | -15.07% | -58.03% | 23.17% | — |
| Operating Margin % | -26.08% | -26.03% | 29.32% | — |
| Gross Margin % | 37.82% | 36.12% | 59.28% | — |
| EBITDA Margin % | -17.28% | -50.98% | 35.17% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.